Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Syed Hamzavi

MOHS-Micrographic Surgery Clinton Twp, MI Medical Doctor

NPI 1295780989 CMS profile 286258

43151 Dalcoma Dr, Suite 1, Clinton Twp, MI 48038

Open in the dashboard

General payments

$4,274

106 records reported · program years 2019–2025

Research payments

$161,628

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,536,627 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Syed Hamzavi of Clinton Twp, MI is reported in the CMS Open Payments database as having received $4,274 across 106 general payments and $161,628 in research payments paid to them. Separately, studies naming them as principal investigator received $5,536,627 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,104 24
2025 Research $37,365 1
2024 General $955 16
2024 Research $122,436 1
2023 General $192 7
2022 General $280 17
2021 General $193 11
2020 General $182 10
2020 Research $322 1
2019 General $368 21
2019 Research $1,505 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Syed Hamzavi
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Syed Hamzavi were reported at $2,104. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Syed Hamzavi MOHS-Micrographic Surgery median Middle half National median
2019 $368 $316 $106–$785 $163
2020 $182 $162 $68–$412 $114
2021 $193 $243 $87–$654 $132
2022 $280 $300 $102–$887 $149
2023 $192 $364 $125–$1,010 $160
2024 $955 $445 $142–$1,108 $164
2025 $2,104 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Insmed, Inc. $1,850 11 payments
  2. Incyte Corporation $728 4 payments
  3. AbbVie, Inc. $420 25 payments
  4. Janssen Biotech, Inc. $215 11 payments
  5. Novartis Pharmaceuticals Corporation $190 12 payments
  6. Kerecis Limited $142 2 payments
  7. Pfizer Inc. $139 9 payments
  8. Genentech USA, Inc. $107 7 payments
  9. LEO Pharma Inc. $101 7 payments
  10. Amgen Inc. $79 3 payments
  11. Other $302 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,807 95 payments
  2. Travel and Lodging $1,658 6 payments
  3. Consulting Fee $680 2 payments
  4. Education $128 3 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $179 9 payments
  2. HUMIRA $167 10 payments
  3. SKYRIZI $141 9 payments
  4. RINVOQ $140 8 payments
  5. STELARA $100 8 payments
  6. CIBINQO $98 6 payments
  7. Erivedge $93 6 payments
  8. Kerecis Omega3 SurgiClose Wound Care $91 1 payment
  9. Kerecis Omega3 SurgiClose Wound Care $91 1 payment
  10. Kerecis Omega3 SurgiClose Wound Care $91 1 payment
  11. Other $1,339 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Nielsen BioSciences, Inc. $159,801 2 payments
  2. Eli Lilly and Company $1,826 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

725

Median for Dermatology: 534

Drug cost

$259,089

Median for Dermatology: $67,151

Branded share of claims

5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 25 $200,666
Dupixent Pen Dupilumab Brand 11 $41,535
Fluorouracil Generic 68 $4,006
Metronidazole Generic 26 $3,014
Clobetasol Propionate Generic 61 $2,438
Betamethasone Dipropionate Generic 38 $1,721
Ketoconazole Generic 67 $1,359
Ammonium Lactate Generic 45 $796
Triamcinolone Acetonide Generic 91 $784
Clindamycin Phosphate Generic 23 $580

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$542,943

Of which drugs: $790

Medicare patients

2,024

Average age 75

Services billed

11,058

1,107 women, 917 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 31%
Diabetes 29%
Chronic kidney disease 24%
COPD 21%
Atrial fibrillation 20%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 58 220 $163
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 21 90 $86

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADBRY
  • LEO Pharma Inc. $47
$47 — —
CIBINQO
  • PFIZER INC. $34
$34 — —
RINVOQ
  • AbbVie, Inc. $18
$18 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $17
$17 25 —
SKYRIZI
  • AbbVie, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record